#3Dmatrix
LightNews LightNews
gregorlab.bsky.social
"It's official 🎉: Our remote magnetic control of #endosomes, driving invasive protrusions in living cells, has landed in #ScienceAdvances! #Magnetogenetics meets #Rabs! The journey was wild, but it works! 🔥 www.science.org/doi/full/10....
@imgprague.bsky.social #3Dmatrix #CellBiology
@science.org
Live-cell magnetic manipulation of recycling endosomes reveals their direct effect on actin protrusions to promote invasive migration
Repositioning of Rab25 vesicles containing formin and integrin cargos to the cell periphery promotes protrusion formation.
www.science.org
July 7, 2025 at 12:58 PM
lostjared.bsky.social
This demo was supposed to be like a Matrix green Rain, but in 3D. It didn't turn out that great. I will have to try again because I don't think it should work the way this program does. You can turn the Web Assembly version of this program here: lostsidedead.biz/3DMatrix/ #matrix #greenrain #3D
December 29, 2025 at 5:01 PM
lesleysmith.bsky.social
Please support Lawrence Wade and colleagues from 3DMatrix who are running the Royal Parks Half Marathon in aid of @prda.org.uk this weekend 👏👏 Every little counts!

www.justgiving.com/fundraising/...
Pelvic Radiation Disease PRDA
Help Lawrence Wade raise money to support PRDA (Pelvic Radiation Disease Association)
www.justgiving.com
October 7, 2025 at 4:02 PM
meagandavid73.bsky.social
Dead dying in a dream simulation #3DMatrix thanks to @cern.bsky.social end of the Mayan calendar in 2025. CERN killed us only way out is #YahushuaBenDavid
December 10, 2025 at 2:14 AM
gregorlab.bsky.social
Gamechanger for vesicle Control! We present an approach to remotely control endosomal distribution in living cells (even in #3Dmatrix) with high precision.
July 7, 2025 at 12:58 PM
lostjared.bsky.social
3D Matrix demo #matrix #demo #glitchart enter the matrix here: lostsidedead.biz/3DMatrix
March 15, 2025 at 5:30 PM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01113695.jpg
#epsteinweb #efta01113695
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA01113695 | EFTA01113695 Science recently learned —50% of medications work through GPCR signaling. But, 99% of existing drugs were discovered by luck: trial, error, observation and testing, over years. Imagine a world in which we could target-design medications to signal through specific GPCR channels. It would change medicin .9 OH2 Laboratories Re-engineering Drug Discovery The ability to produce stable water-soluble protein replicants is a fundamental new tool that opens many doors: Drug Discovery Our technology provides a critical revitalization of drying pharma pipelines: (i) Addresses compounds with poor solubility (over 40% of drugs) offering increased efficacy and faster, cheaper development. (ii) Enables novel drug candidates for GPCR-mediated diseases: *Examples include: Alzheimer's (GPR3) Parkinson's (GPCR 37) Prostate cancer (GPR68/0GRI) Arteriosclerosis (GPRS 176) Asthma (CCR3.CXCR2) Cancer metastasis (CXCR4) Colon cancer (MASI) Ovarian Cancer (OCRI) Leukemia (P2Y8/P2 R Y8) Diabetes (GPCR 21) Autism (GPCR 63) Bipolar disorder (GPRS 78) Osteoarthritis (GPR22) Lung cancer (GPR87) Breast Cancer (CXCR4) (Plus over 700 others and the list grows almost daily.) Research Tools - Provide our synthetic GPCRQTY materials, duplicating native GPCR functionality in a water-soluble form to research laboratories. Diagnostics - Water-soluble GPCRQTY materials maintain ligand binding ability to specific antigens/receptors, providing a new class of novel, low-cost diagnostics. Company Structure OH2 is an IP development and holding company, structured to form subsidiaries to monetize the benefits our technologies bring to a range of fields: • Drug Discovery • Research Tools • Diagnostics • mAB-Similar Products • Autoimmune/Allergy Therapy • Viral Therapeutics • Molecular Sensors Market Size (Pharma only) GPCR-related pharma is —$425B/year globally. Our technology will grow the market considerably. Our Scientists Shuguang Zhang, Ph.D - Lead Investigator MIT Researcher for 26 years 160 papers, 36 patents issued and pending Last company (3DMatrix) valued at 5800M Prof. Robert Langer mAB-Similar Products - New molecular therapeutics: (i) Target-designed to be similar to monoclonal antibodies, but easier to produce; (ii) Engineering mAbQTY to reduce mAb aggregation and increase long-term storage. MIT Professor for 36 years 1,250+ articles. 220+ major awards 1,030+ patents. 250+ licenses Autoimmune/Allergy Therapy - Use GPCRQTY as decoy treatment (similar to Enbrel/Etanercept), theoretically for any disease or condition associated with GPCR signaling. David Jin, M.D. Viral Therapeutics - Use Receptors QTY to trap viruses including: HIV, Ebola, Marburg & Lassa - for rapid reduction of viral loads. Molecular Sensors - Use Receptors QTY to create ultra-sensitive bionic detectors. (e.g. a chip-based bionic nose.) For more information contact David Levy Alexander Rich, M.D. MIT Professor for 56 years 550+ articles. Many awards and honors Practicing Oncologist and Researcher 2012 Top Chief Medical Officer in America 2014 Leading Physicians in the World Our Board David Levy, Ph.D - General Manager and Chairman Marc Rioult, Ph.D - Man. Director, 3DMatrix US & Europe Kevin Munnelly, Ph.D - President and CEO, Gen9 Steve Yang, Ph.D. - Director, Sentilia +1 EFTA01113695 Epstein Web iOS app on the App Store.
May 9, 2026 at 9:29 PM